<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="407">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000853</url>
  </required_header>
  <id_info>
    <org_study_id>IDIBELL - EOM019/21</org_study_id>
    <nct_id>NCT05000853</nct_id>
  </id_info>
  <brief_title>New Pathophysiological Pathways Involved in Iron Metabolism Disorder in Heart Failure</brief_title>
  <acronym>IRON-PATH II</acronym>
  <official_title>New Pathophysiological Pathways Involved in Iron Metabolism Disorder in Heart Failure: The IRON-PATH II Investigator Initiated Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to understand the biological pathways involved in the occurrence of&#xD;
      IDy in patients with HF since ID is very common and supposes a negative impact in terms of&#xD;
      clinical outcomes in these patients. In this context, a deeper understanding of the&#xD;
      mechanisms involved in the development of ID in these patients and the impact on the altered&#xD;
      biological pathways after iron replenishment will pave the way for an improvement and&#xD;
      simplification of the preventive strategies in patients with HF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IRON-PATH II Project is a pre-clinical and clinical study designed as a multicenter,&#xD;
      prospective, observational (non-interventional), investigator initiated study. The total&#xD;
      number of patients to be recruited will be 210 (80 patients without ID and 130 patients with&#xD;
      ID). Patients will be recruited during 12 months in 7 centers across Spain and Portugal and&#xD;
      followed for a fixed period of 12 months. The primary objective of the clinical study is to&#xD;
      define pathways associated with systemic and tissue ID in HF patients compared with non-ID HF&#xD;
      patients and explore the change in the patterns of pathway activation/suppression after irons&#xD;
      status normalization in ID patients with intravenous iron treatment using an integrative&#xD;
      omics and systems biology approach including whole-genome analysis of gene expression&#xD;
      (transcriptome), protein synthesis (proteomics) and metabolic characterization (metabolomics)&#xD;
      from blood samples. Key secondary objectives will include changes in patient-reported&#xD;
      outcomes (PROMs) such as QoL, patient-reported experience measures (PREMs), the occurrence of&#xD;
      events, among others between those with and without ID. The aims of the pre-clinical study is&#xD;
      to confirm previous findings of the IRONPATH I study and to explore in vitro interventions in&#xD;
      cardiac cells models with iron deficiency.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>To define pathways associated with iron deficiency (ID) in heart failure (HF) patients compared with non-ID HF patients</measure>
    <time_frame>Twelve months after inclusion the patient</time_frame>
    <description>Using an integrative omics and systems biology approach including whole-genome analysis of gene expression (transcriptome), protein synthesis (proteomics) and metabolic characterization (metabolomics) from blood samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Biomarkers (New York Heart Association [NYHA)</measure>
    <time_frame>Twelve months after inclusion the patient</time_frame>
    <description>Comparison between ID and non ID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of self-care using a validated scale (European Heart Failure Self-Care Behavior Scale).</measure>
    <time_frame>Twelve months after inclusion the patient</time_frame>
    <description>Comparison between ID and non ID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported experience measures (PREMs) (IEXPAC)</measure>
    <time_frame>Twelve months after inclusion the patient</time_frame>
    <description>Comparison between ID and non ID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic biomarkers (NT-proBNP)</measure>
    <time_frame>Twelve months after inclusion the patient</time_frame>
    <description>Comparison between ID and non ID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of events (all-cause death, HF-clinically related admissions, CV admissions)</measure>
    <time_frame>Twelve months after inclusion the patient</time_frame>
    <description>Comparison between ID and non ID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Biomarkers (6-minutes walking test [6MWT] distance)</measure>
    <time_frame>Twelve months after inclusion the patient</time_frame>
    <description>Comparison between ID and non ID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of quality of life using a validated questionnaire (EUROQOL - 5D)</measure>
    <time_frame>Twelve months after inclusion the patient</time_frame>
    <description>Comparison between ID and non ID patients</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Patients with iron deficiency</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without iron deficiency</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Carboxymaltose</intervention_name>
    <description>Iron supplementation when is needed according to usual care</description>
    <arm_group_label>Patients with iron deficiency</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study cohort will be a multicenter, observational, prospective, cross-sectional and&#xD;
        longitudinal nested case-control sample of 210 patients with (130 cases) and without (80&#xD;
        controls) ID according to the FAIR-HF (27) (serum ferritin &lt;100 mg/L or transferrin&#xD;
        saturation [%TSAT]&lt;20% if ferritin is between 100-300mg/L), recruited for the specific&#xD;
        purpose of the IRON-PATH II study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old.&#xD;
&#xD;
          -  HF diagnosis according to European Society of Cardiology&#xD;
&#xD;
          -  LVEF≤50% (systolic HF).&#xD;
&#xD;
          -  Patients receiving oral standard medication for chronic HF.&#xD;
&#xD;
          -  Iron status evaluated in the last 3 months.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&lt;18 years old.&#xD;
&#xD;
          -  Intravenous or oral iron administration or under treatment with ESA&#xD;
             (erythropoiesis-stimulating agents) in the previous 3 months.&#xD;
&#xD;
          -  Planned cardiac resynchronization therapy (CRT), revascularization and other major&#xD;
             interventions including heart transplant or left ventricular assist device (LVAD)&#xD;
             implantation in the next 3 months in patients with ID.&#xD;
&#xD;
          -  Planned uptitration of guideline-mandatory HF-modifying drugs in the next 3 months&#xD;
             (except iron repletion) in patients with ID.&#xD;
&#xD;
          -  Moderate or severe anaemia (Hb&lt;11 g/dL).&#xD;
&#xD;
          -  The patient is unable or unwilling to give the informed consent to participate.&#xD;
&#xD;
          -  Unstable patients with signs of fluid overload or low cardiac output at the moment of&#xD;
             enrollment.&#xD;
&#xD;
          -  Life expectancy less than 1 year (excluding HF).&#xD;
&#xD;
          -  The patient is considered not to be an adequate candidate for this study according to&#xD;
             the decision of the local investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Comin Colet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bellvitge Biomedical Research Institute (IDIBELL) - Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josep Comin Colet, MD, PhD</last_name>
    <phone>+34 932607078</phone>
    <email>jcomin@bellvitgehospital.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria del Mar Ras Jimenez, MD</last_name>
    <phone>+34 932607078</phone>
    <email>mras@bellvitgehospital.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvtige</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep R Comin, MD, PhD</last_name>
      <phone>+34-933-35-70-11</phone>
      <phone_ext>2274</phone_ext>
      <email>jcomin@bellvitgehospital.cat</email>
    </contact>
    <contact_backup>
      <last_name>Maria del Mar Ras Jimenez, MD</last_name>
      <phone>+34-933-35-70-11</phone>
      <phone_ext>2274</phone_ext>
      <email>mras@bellvitgehospital.cat</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Comín Colet, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Josep Comín</investigator_full_name>
    <investigator_title>Prof. Josep Comín-Colet, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Iron Deficiency</keyword>
  <keyword>Machine Learning</keyword>
  <keyword>Multi-Omics Approaches</keyword>
  <keyword>Outcomes Research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Iron Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

